Higher vaccination rates predict reduction in SARS-CoV-2 transmission across the United States

被引:5
作者
Au, Jacky [1 ]
机构
[1] Univ Calif Irvine, Sch Educ, 3200 Educ Bldg, Irvine, CA 92697 USA
基金
美国国家卫生研究院;
关键词
COVID-19; SARS-CoV-2; Pandemic; Vaccines;
D O I
10.1007/s15010-022-01802-1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began proliferating widely throughout the world in late 2019/early 2020, creating a global pandemic and health crisis. Although vaccines became available to the public approximately 1 year after the onset of the pandemic, there still remains much hesitancy surrounding vaccination. One key concern comes from reports of breakthrough infections among the vaccinated that show comparable levels of peak viral load as the unvaccinated, calling into question the ability of vaccines to prevent transmission. Therefore young, healthy individuals who are at low risk of serious complications themselves have little incentive to receive a vaccine that they are not convinced will protect others around them. To address this important concern, this study aimed to evaluate the extent to which vaccination rates are associated with reduced SARS-CoV-2 transmission among the unvaccinated population. Methods An observational study was conducted in the United States of America throughout the months of June through September, 2021. Vaccination rate and incidence of coronavirus disease 2019 (COVID-19) were obtained for each state, along with a number of important control variables. Panel data regression was used to predict incidence among the unvaccinated based on each state's vaccination rate. Results States with a higher proportion of fully vaccinated individuals reported fewer new cases among the remaining unvaccinated population. Conclusion These data add to accumulating evidence that COVID-19 vaccinations can indeed slow the spread of SARS-CoV-2, and are an important tool in society's arsenal to put this pandemic behind us.
引用
收藏
页码:1255 / 1266
页数:12
相关论文
共 40 条
[1]   Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].
Baden, Lindsey R. ;
El Sahly, Hana M. ;
Essink, Brandon ;
Kotloff, Karen ;
Frey, Sharon ;
Novak, Rick ;
Diemert, David ;
Spector, Stephen A. ;
Rouphael, Nadine ;
Creech, C. Buddy ;
McGettigan, John ;
Khetan, Shishir ;
Segall, Nathan ;
Solis, Joel ;
Brosz, Adam ;
Fierro, Carlos ;
Schwartz, Howard ;
Neuzil, Kathleen ;
Corey, Larry ;
Gilbert, Peter ;
Janes, Holly ;
Follmann, Dean ;
Marovich, Mary ;
Mascola, John ;
Polakowski, Laura ;
Ledgerwood, Julie ;
Graham, Barney S. ;
Bennett, Hamilton ;
Pajon, Rolando ;
Knightly, Conor ;
Leav, Brett ;
Deng, Weiping ;
Zhou, Honghong ;
Han, Shu ;
Ivarsson, Melanie ;
Miller, Jacqueline ;
Zaks, Tal .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416
[2]   Potential problems in the statistical control of variables in organizational research: A qualitative analysis with recommendations [J].
Becker, TE .
ORGANIZATIONAL RESEARCH METHODS, 2005, 8 (03) :274-289
[3]   Covid-19 Breakthrough Infections in Vaccinated Health Care Workers [J].
Bergwerk, Moriah ;
Gonen, Tal ;
Lustig, Yaniv ;
Amit, Sharon ;
Lipsitch, Marc ;
Cohen, Carmit ;
Mandelboim, Michal ;
Gal Levin, Einav ;
Rubin, Carmit ;
Indenbaum, Victoria ;
Tal, Ilana ;
Zavitan, Malka ;
Zuckerman, Neta ;
Bar-Chaim, Adina ;
Kreiss, Yitshak ;
Regev-Yochay, Gili .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) :1474-1484
[4]  
Brown CM, 2021, MMWR-MORBID MORTAL W, V70, P1059, DOI 10.15585/mmwr.mm7031e2
[5]   Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study [J].
Chia, Po Ying ;
Ong, Sean Wei Xiang ;
Chiew, Calvin J. ;
Ang, Li Wei ;
Chavatte, Jean-Marc ;
Mak, Tze-Minn ;
Cui, Lin ;
Kalimuddin, Shirin ;
Chia, Wan Ni ;
Tan, Chee Wah ;
Chai, Louis Yi Ann ;
Tan, Seow Yen ;
Zheng, Shuwei ;
Lin, Raymond Tzer Pin ;
Wang, Linfa ;
Leo, Yee-Sin ;
Lee, Vernon J. ;
Lye, David Chien ;
Young, Barnaby Edward .
CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (04) :612.e1-612.e7
[6]   Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization [J].
Chodick, Gabriel ;
Tene, Lilac ;
Patalon, Tal ;
Gazit, Sivan ;
Ben Tov, Amir ;
Cohen, Dani ;
Muhsen, Khitam .
JAMA NETWORK OPEN, 2021, 4 (06) :E2115985
[7]   Should I Use Fixed or Random Effects? [J].
Clark, Tom S. ;
Linzer, Drew A. .
POLITICAL SCIENCE RESEARCH AND METHODS, 2015, 3 (02) :399-408
[8]   BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting [J].
Dagan, Noa ;
Barda, Noam ;
Kepten, Eldad ;
Miron, Oren ;
Perchik, Shay ;
Katz, Mark A. ;
Hernan, Miguel A. ;
Lipsitch, Marc ;
Reis, Ben ;
Balicer, Ran D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (15) :1412-1423
[9]   Mask adherence and rate of COVID-19 across the United States [J].
Fischer, Charlie B. ;
Adrien, Nedghie ;
Silguero, Jeremiah J. ;
Hopper, Julianne J. ;
Chowdhury, Abir, I ;
Werler, Martha M. .
PLOS ONE, 2021, 16 (04)
[10]   Death by political party: The relationship between COVID-19 deaths and political party affiliation in the United States [J].
Gao, Jingjing ;
Radford, Benjamin J. .
WORLD MEDICAL & HEALTH POLICY, 2021, 13 (02) :224-249